Hangzhou Tigermed Consulting Co., Ltd (SHE: 300347)

Market Cap	51.95B
Revenue (ttm)	6.80B
Net Income (ttm)	958.67M
Shares Out	861.29M
EPS (ttm)	1.11
PE Ratio	58.57
Forward PE	33.61
Dividend	0.57 (0.87%)
Ex-Dividend Date	Jul 12, 2024

Volume	91,711
Open	64.78
Previous Close	60.05
Day's Range	60.48 - 64.78
52-Week Range	36.12 - 82.79
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data managem...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 9,701
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2023, Hangzhou Tigermed Consulting's revenue was 7.38 billion, an increase of 4.21% compared to the previous year's 7.09 billion. Earnings were 2.02 billion, an increase of 0.91%.